AndroGel testosterone supplement lawsuits continue to progress in an Illinois
U.S. District Court overseen by Judge Matthew Kennelly. The coordination
of more than 1,500 lawsuits is involved in this MDL. The MDL was established
a little more than a year ago with an eye toward streamlining early trial
proceedings. Judge Kennelly denied bifurcation requests to separate the
liability question from the damages for injuries into two separate trials on May 29th, 2015.
AndroGel manufactured by AbbVie is currently the largest-selling testosterone
replacement product on the market. Judge Kennelly also lengthened the
bellwether selection process, and divided the cases into two groups: those
which allege blood clot injuries, thromboembolism and deep vein thrombosis
and those which allege heart attacks caused by testosterone supplements.
A final order will be issued regarding bellwether case selection on August 31st.
Following this order, plaintiffs and defendants will each submit a list
of eight potential bellwether cases, and the court will choose three from
each group for early trial. Trial dates for Androgel lawsuits involving
thromboembolism are set for October 2016, December 2016 and January 2017.
Trial dates for heart attack lawsuits regarding AndroGel are set for February
2017, March 2017 and April 2017.
What is “Low-T” and How Does AndroGel Help?
AndroGel is a daily testosterone replacement drug which, according to the
manufacturer, will help bring testosterone levels back to normal with
daily use. Since 2001, the number of prescriptions for testosterone supplements
has more than quadrupled, with 5 million prescriptions in 2013 alone.
AndroGel has more than half of the entire testosterone market, generating
more than $1 billion in sales in 2013. Abbot Laboratories and AbbVie spent
more than $80 million in advertising costs for Androgel in 2013. AndroGel
gained FDA approval in 2000 for men with a medical diagnosis of hypogonadism,
yet less than half of the men currently taking AndroGel—or any other
testosterone supplement—actually have such a diagnosis.
Testosterone manufacturers have aggressively marketed their supplements
for off-label use, claiming that men of all ages who are tired, have less
muscle and more belly fat, have a low sex drive or less bone density can
benefit from taking a testosterone supplement. In fact, all of these issues
are the natural effects of aging, as testosterone levels drop from the
time a man reaches the age of thirty. Due to such advertising tactics,
many men see testosterone supplements as a veritable fountain of youth,
unaware of the potential dangers associated with the supplements.
Potential Risks of AndroGel
A study published in November 2013 in the Journal of American Medical Association
linked testosterone supplements to a 29% greater risk of heart attack,
stroke and even death. Another study published in August 2013, concluded
there was an increase in blood clots for those men taking testosterone
supplements like AndroGel. Adding a testosterone supplement can increase
the thickness of the blood, leading to excess blood clotting, deep vein
thrombosis, and pulmonary embolism.
The first six lawsuits filed against AbbVie and Abbot alleged three heart
attacks, one stroke, one mini-stroke and blood clots. Less serious—but
still troubling—side effects of AndroGel include acne, reduced sperm
count, loss of hair, vertigo, enlargement of the breasts, weight gain,
agitation, hostility, chronic headaches, worsening of sleep apnea symptoms
and stomach and abdominal pain.
National Dangerous Drug Lawyers
If you have suffered a heart attack or cardiac complication from AndroGel
or other testosterone supplement, it can be very beneficial to speak to
an experienced Philadelphia class action lawyer to determine what options
are available to you. Drug companies who routinely put profits before
people should pay for their negligence—and their unscrupulous behavior.
To learn more about your legal options or to schedule a free consultation call the
Philadelphia product liability lawyers at Golomb & Honik today at
1-800-355-3300 or 1-215-985-9177 or fill out our confidential
The national dangerous drug lawyers at Golomb & Honik have successfully
represented individuals in Philadelphia, Pennsylvania, New Jersey, and
throughout the United States.